2023-08-24 12:38:29 ET
More on Collegium Pharmaceutical
- Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates
- With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy
- Collegium Pharmaceutical, Inc. ( COLL ) Q2 2023 Earnings Call Transcript
- Collegium Pharmaceutical, Inc. 2023 Q2 - Results - Earnings Call Presentation
- FDA updates safety requirements for opioid pain meds
- Collegium stock falls ~10% after announcing intention for $175M notes offering
- Collegium Pharmaceutical sees 65% growth in product revenue post BioDelivery acquisition: 2022 Guidance
- Collegium Pharmaceutical Q4 2021 Earnings Preview
- Seeking Alpha’s Quant Rating on Collegium Pharmaceutical
- Earnings data for Collegium Pharmaceutical
For further details see:
Collegium pain med Nucynta gets US market exclusivity extension